Drugs / Arbaclofen
Arbaclofen
also known as
STX209 · AERT · Arbaclofene · Arbaclofeno · Baclofen (r)-form · D-baclofen · R-baclofen
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02278328 | Feb 2016 → Jul 2018 | autism | Timothy Roberts | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01172509 | Oct 2010 → Jul 2012 | autism | Gonzalez-Heydrich, Joseph, M.D. | Terminated | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04271332 | Sep 2022 → Dec 2024 | proximal 16p11.2 microdeletion syndrome | Clinical Research Associates, LLC | Unknown | No outcome recorded |
| Phase 2 | NCT03682978 | Sep 2019 → Jan 2023 | autism spectrum disorder | Celso Arango, MD, PhD | Completed | Missed primary |
| Phase 2 | NCT01064973 | Feb 2010 → Dec 2012 | autism spectrum disorder | Seaside Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00846547 | Feb 2009 → Jun 2010 | autism spectrum disorder | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07655115 | Nov 2025 → Dec 2026 expected | autism spectrum disorder | Hospital General Universitario Gregorio Marañon | Recruiting | No outcome recorded |
| Phase 3 | NCT03319732 | Apr 2018 → Jan 2020 | multiple sclerosis | RVL Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02869425 | Jul 2016 → Oct 2018 | multiple sclerosis | RVL Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01844232 | Apr 2013 → Dec 2014 | multiple sclerosis | RVL Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01743651 | Nov 2012 → Apr 2014 | multiple sclerosis | RVL Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01555333 | Nov 2011 → Jul 2013 | fragile X syndrome | Seaside Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01706523 | Nov 2011 → Jul 2013 | autism spectrum disorder | Seaside Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03594552 | Feb 2018 → Mar 2020 | autism spectrum disorder | King's College London | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT03887676 Comparator | Mar 2019 → Aug 2023 | autism spectrum disorder | Holland Bloorview Kids Rehabilitation Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01288716 Comparator | May 2011 → Aug 2012 | autism spectrum disorder | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01013480 Comparator | Nov 2009 → Dec 2012 | fragile X syndrome | Seaside Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00788073 Comparator | Nov 2008 → Mar 2010 | fragile X syndrome | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05179577 Comparator | Jan 2027 → Jan 2028 expected | — | RVL Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03290131 Comparator | Jan → Dec 2018 | multiple sclerosis | RVL Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01325220 Comparator | Jun 2011 → Jun 2013 | fragile X syndrome | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01282268 Comparator | May 2011 → Dec 2012 | fragile X syndrome | Seaside Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arbaclofen | “STX209 (arbaclofen)” NCT01706523 ↗ |
| Known as | AERT | “The primary safety objective is to assess the effects of arbaclofen ER tablets (AERT) compared with placebo on sperm concentration from baseline to the end of 90 days of...” NCT02869425 ↗ |
| Known as | Arbaclofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL301742 ↗ |
| Known as | Arbaclofeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL301742 ↗ |
| Known as | Baclofen (r)-form | ChEMBL registry synonym — accepted as the source's own label CHEMBL301742 ↗ |
| Known as | D-baclofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL301742 ↗ |
| Known as | R-baclofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01172509 ↗ |
| Known as | STX209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00788073 ↗ |
| Action | Activate | “STX209, a GABA-B agonist” NCT02278328 ↗ |
| Modality | Small molecule | — CHEMBL301742 ↗ |
| Route | Oral | “Capsule, Oral, 4 weeks” NCT00788073 ↗ |